Recordati Rare Diseases España

Recordati Rare Diseases España company information, Employees & Contact Information

En Recordati Rare Diseases nos centramos en una minoría: los afectados por las enfermedades raras (poco frecuentes, minoritarias). Creemos que todos y cada uno de los pacientes tienen derecho al acceso al mejor tratamiento posible. Los pacientes con enfermedades raras poco frecuentes son nuestra mayor prioridad. Nuestra planificación, nuestros pensamientos y nuestras acciones giran en torno a ellos.

Company Details

Employees
16
Address
Madrid, Es
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Madrid
Looking for a particular Recordati Rare Diseases España employee's phone or email?

Recordati Rare Diseases España Questions

News

Recordati Rare Diseases touts new data in Cushing’s syndrome - The Pharma Letter

Recordati Rare Diseases touts new data in Cushing’s syndrome The Pharma Letter

RECORDATI RARE DISEASES: CARBAGLU® (Carglumic Acid) Tablets 200mg Receives U.S. FDA Approval for a New Indication to Treat Acute Hyperammonemia Associated with Propionic Acidemia and Methylmalonic Acidemia - PR Newswire

RECORDATI RARE DISEASES: CARBAGLU® (Carglumic Acid) Tablets 200mg Receives U.S. FDA Approval for a New Indication to Treat Acute Hyperammonemia Associated with Propionic Acidemia and Methylmalonic Acidemia PR Newswire

Cystadrops Approved to Treat Corneal Crystal Deposits in Cystinosis - Medical Professionals Reference

Cystadrops Approved to Treat Corneal Crystal Deposits in Cystinosis Medical Professionals Reference

Recordati Rare Diseases Announces Availability of CYSTADROPS® (Cysteamine Ophthalmic Solution) 0.37% in the U.S. - PR Newswire

Recordati Rare Diseases Announces Availability of CYSTADROPS® (Cysteamine Ophthalmic Solution) 0.37% in the U.S. PR Newswire

Recordati Rare Diseases Announces First European Launch of Isturisa® (osilodrostat) - NTB Kommunikasjon

Recordati Rare Diseases Announces First European Launch of Isturisa® (osilodrostat) NTB Kommunikasjon

Recordati Rare Diseases Partners With the National Urea Cycle Disorders Foundation To Increase Awareness of the Risks of Hyperammonemia - PR Newswire

Recordati Rare Diseases Partners With the National Urea Cycle Disorders Foundation To Increase Awareness of the Risks of Hyperammonemia PR Newswire

Recordati: Isturisa® (Osilodrostat) Approved In The U.S. - PR Newswire

Recordati: Isturisa® (Osilodrostat) Approved In The U.S. PR Newswire

Top Recordati Rare Diseases España Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant